Test your knowledge
Module 5: QUVIVIQ™ in practice: patient cases
Introduction
Cognitive behaviour therapy for insomnia (CBTi) is recommended first line for patients with chronic insomnia.1 This approach has proven successful in relieving symptoms associated with insomnia, however for some patients, pharmacological management may also be needed (although this is not usually recommended in the long term).1,2
There are well-documented risks associated with hypnotics commonly prescribed for insomnia, including falls (especially in the elderly), cognitive impairment and dependence; contraindications and cautions also limit use in several patient populations.3-5 A more recent addition to the insomnia treatment arsenal is the dual orexin receptor antagonist, QUVIVIQ™, which is recommended for use after CBTi in eligible patients.6,7
Learning objectives
By completing this module, you will increase your awareness and understanding of:
- early management approaches for chronic insomnia
- appropriate monitoring and assessment
- pharmacological treatment selection depending on patient characteristics
- which patients could benefit from QUVIVIQ™
Multiple-choice questions to test your current knowledge
These questions will help you assess your current knowledge of this topic before you begin to work on the module. Your answers will be marked but will not count towards your final score. You will be asked the same questions again at the end of the module and will be able to download a learning certificate for your records upon completion.
Ready for the next step?
Managing chronic insomnia in a postmenopausal female
CBTi: cognitive behavioural therapy for insomnia
QUVIVIQ™ is indicated for the treatment of adult patients with insomnia characterised by symptoms present for at least 3 months and considerable impact on daytime functioning.6
This information is intended for UK healthcare professionals.
Adverse events must be reported. Healthcare professionals are asked to report any suspected adverse reactions via www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to ds.safety.uk@idorsia.com
References
- National Institute for Health and Care Excellence (NICE). Clinical knowledge summary. Insomnia: managing long‑term insomnia (more than 3 months duration), May 2025. Available at: cks.nice.org.uk. Accessed August 2025
- Riemann D, Espie C A et al. The European Insomnia Guideline: an update on the diagnosis and treatment of insomnia 2023. J Sleep Res 2023;32(6):e14035
- National Institute for Health and Care Excellence (NICE). Clinical knowledge summary. Insomnia. Prescribing information: Z-drugs, May 2025. Available at: cks.nice.org.uk. Accessed August 2025
- British National Formulary (BNF). Diazepam. Available at: bnf.nice.org.uk. Accessed August 2025
- British National Formulary (BNF). Hypnotics and anxiolytics. Available at: bnf.nice.org.uk. Accessed August 2025
- QUVIVIQ™ Idorsia Pharmaceuticals Ltd, Summary of Product Characteristics
- National Institute for Health and Care Excellence (NICE). Technology appraisal guidance 922. Daridorexant for treating long-term insomnia, 18 October 2023. Available at: nice.org.uk. Accessed August 2025
© NICE 2023 Daridorexant for treating long-term insomnia. Available from www.nice.org.uk/guidance/ta922. All rights reserved. Subject to Notice of rights.
NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/ publication.
UK-DA-00657 | Date of preparation: September 2025
